Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment - PubMed
6 hours ago
- #durvalumab
- #bladder cancer
- #cost-effectiveness
- Perioperative durvalumab with neoadjuvant gemcitabine/cisplatin improves survival in cisplatin-eligible muscle-invasive bladder cancer.
- The treatment is cost-effective, with lower total costs compared to standard care.
- Benefits include greater life years and quality-adjusted life years.
- Higher upfront costs are offset by reduced postprogression expenses.
- Sensitivity analyses confirm robustness of cost-effectiveness findings.